- TG Therapeutics (TGTX, Financial) will present new BRIUMVI® data at the 2025 CMSC Annual Meeting.
- The key presentations will focus on long-term ublituximab treatment, real-world infusion tolerability, and safety of 30-minute infusions.
- All presentations are scheduled for May 29, 2025, in Phoenix, Arizona.
TG Therapeutics, Inc. (TGTX) is set to showcase three significant studies on BRIUMVI® (ublituximab-xiiy) during the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, which runs from May 28 to May 31, 2025, in Phoenix, Arizona. According to the company's announcement, these studies will provide insights into the drug's efficacy and safety in treating multiple sclerosis (MS).
One of the core presentations, led by Dr. Bruce Cree, will discuss the correlation between serum immunoglobulin levels and infections during long-term ublituximab treatment. Another presentation by Dr. Edward Fox will delve into infusion tolerability, using data from the ENAMOR real-world observational survey. Dr. John Foley will present updated safety and tolerability data from the ENHANCE study, focusing on 30-minute ublituximab infusions.
These presentations are all scheduled for May 29, 2025, and will be accessible on TG Therapeutics' website following the event. This series of presentations underscores TG Therapeutics' commitment to advancing treatment options for relapsing forms of multiple sclerosis, with BRIUMVI positioning as a promising therapeutic agent.
